NO-and haem-independent soluble guanylate cyclase activators
Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …
[HTML][HTML] Soluble guanylate cyclase stimulators and activators
P Sandner, DP Zimmer, GT Milne, M Follmann… - Reactive oxygen …, 2021 - Springer
Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …
Soluble guanylate cyclase stimulators and activators: where are we and where to go?
Soluble Guanylate Cyclase (sGC) is the intracellular receptor of Nitric Oxide (NO). The
activation of sGC results in the conversion of Guanosine Triphosphate (GTP) to the …
activation of sGC results in the conversion of Guanosine Triphosphate (GTP) to the …
NO-independent, haem-dependent soluble guanylate cyclase stimulators
The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …
Heme-dependent and independent soluble guanylate cyclase activators and vasodilation
FBM Priviero, RC Webb - Journal of cardiovascular pharmacology, 2010 - journals.lww.com
Since the discovery of nitric oxide (NO), which is released from endothelial cells as the main
mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus …
mediator of vasodilation, its target, the soluble guanylyl cyclase (sGC), has become a focus …
[HTML][HTML] From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
P Sandner - Biological chemistry, 2018 - degruyter.com
Nitric oxide (NO) signaling represents one of the major regulatory pathways for
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …
Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease
Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …
Soluble guanylate cyclase stimulators and their potential use: a patent review
P Sandner, A Vakalopoulos, MG Hahn… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: In 2013, riociguat a potent and specific stimulator of the soluble guanylyl
cyclase (sGC) was approved as first in class sGC stimulator which reflected a first …
cyclase (sGC) was approved as first in class sGC stimulator which reflected a first …
NO‐and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle
Soluble guanylyl cyclase (sGC) is the only proven receptor for the ubiquitous biological
messenger nitric oxide (NO) and is intimately involved in many signal transduction …
messenger nitric oxide (NO) and is intimately involved in many signal transduction …
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential
Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …